Top Page
Helix BioPharma
(TSX:HBP)
Helix BioPharma (HBP) vs. iShares MSCI Canada ETF (EWC)
Helix BioPharma Business Overview & Revenue Model
Helix BioPharma Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -6.00K | -14.00K | -13.00K | -12.00K | -173.00K | -212.00K | EBIT |
| -8.40M | -9.37M | -6.28M | -6.54M | -9.61M | -8.59M | EBITDA |
| -9.83M | -9.38M | -6.31M | -6.03M | -9.46M | -8.44M | Net Income Common Stockholders |
| -9.82M | -9.26M | -6.29M | -6.08M | -7.91M | -9.01M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 120.00K | 1.08M | 808.00K | 3.25M | 3.56M | 4.24M | Total Assets |
| 344.00K | 1.49M | 1.03M | 3.73M | 4.07M | 4.91M | Total Debt |
| 0.00 | 0.00 | 0.00 | 2.47M | 3.61M | 159.00K | Net Debt |
| -120.00K | -1.08M | -808.00K | -784.00K | 47.00K | -4.08M | Total Liabilities |
| 603.00K | 1.58M | 1.87M | 3.41M | 5.46M | 1.93M | Stockholders Equity |
| -259.00K | -90.00K | -844.00K | 319.00K | -1.39M | 2.39M |
| Cash Flow | Free Cash Flow | ||||
| -3.68M | -5.23M | -5.54M | -6.51M | -9.30M | -10.84M | Operating Cash Flow |
| -3.67M | -5.22M | -5.53M | -6.51M | -9.30M | -10.83M | Investing Cash Flow |
| 15.00K | -14.00K | -5.00K | 0.00 | 2.02M | 1.70M | Financing Cash Flow |
| 5.52M | 5.51M | 3.09M | 6.21M | 6.56M | 13.10M |
Helix BioPharma Technical Analysis
Helix BioPharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | C$64.98M | 16.84 | 14.51% | ― | 28.97% | ― | |
68 Neutral | C$42.94M | 26.29 | 5.32% | ― | -4.67% | -60.94% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
43 Neutral | C$25.95M | ― | -478.64% | ― | ― | 56.78% | |
33 Underperform | C$68.22M | ― | 685.26% | ― | ― | -50.29% | |
30 Underperform | $44.87M | ― | 281.56% | ― | ― | 71.24% |
Helix BioPharma Corporate Events
Helix BioPharma Corp. has announced the appointment of Veronika Kandziora as Chief Operating Officer and Jessica Kourniaktis as Director of Communications. These strategic appointments are aimed at accelerating the company’s growth and enhancing its mission to address hard-to-treat cancers. Kandziora brings extensive leadership experience and deep institutional knowledge, while Kourniaktis offers a unique blend of communication expertise and life sciences insight. These changes are expected to strengthen Helix’s operational structure and stakeholder engagement, positioning the company for future success in the oncology sector.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Underperform.
Helix BioPharma faces significant financial challenges with continuous losses and no revenue generation, severely impacting its overall score. Technical indicators suggest weak market momentum, and the valuation metrics highlight the company’s lack of profitability. However, recent corporate events provide a glimpse of potential strategic improvements, though they are insufficient to outweigh the financial concerns.
To see Spark’s full report on TSE:HBP stock, click here.
Helix BioPharma Corp. has appointed Dr. Thomas Mehrling as its new CEO to lead the company’s ambitious clinical development plans. Dr. Mehrling, with extensive experience in pharmaceutical oncology, aims to advance Helix’s pipeline, including the L-DOS47 Phase II study for non-small cell lung cancer. This strategic leadership change is expected to strengthen Helix’s position in the oncology industry and support its growth objectives.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Underperform.
Helix BioPharma faces significant financial challenges with continuous losses and no revenue generation, severely impacting its overall score. Technical indicators suggest weak market momentum, and the valuation metrics highlight the company’s lack of profitability. However, recent corporate events provide a glimpse of potential strategic improvements, though they are insufficient to outweigh the financial concerns.
To see Spark’s full report on TSE:HBP stock, click here.
Helix BioPharma Corp. has engaged Independent Trading Group (ITG) to provide market-making services to enhance the liquidity of its common shares, subject to regulatory approval. This agreement, which involves ITG trading shares on the TSX and other venues, aims to maintain a reasonable market for Helix’s shares, potentially improving the company’s market presence and attractiveness to investors.
Helix BioPharma Corp. announced the results of its Annual General and Special Meeting, where shareholders voted overwhelmingly in favor of all business items. Key resolutions approved include the re-election of directors, appointment of auditors, asset transactions, a financing facility, a share consolidation, and a company name change to ‘Aconara Pharma Corp.’ These decisions are poised to impact the company’s operational strategies and market positioning, potentially enhancing its financial flexibility and corporate identity.
Helix BioPharma Corp. announced the filing of its unaudited interim financial statements for the three and six-month periods ending January 31, 2025. This filing includes the management’s discussion and analysis and certifications from the CEO and CFO. The release of these financial statements is a routine disclosure that provides stakeholders with insights into the company’s financial health and operational progress, potentially impacting investor confidence and market positioning.
Helix BioPharma Corp. announced a poster presentation at the European Molecular Imaging Meeting in Bilbao, Spain, showcasing the effects of its Tumour Defence Breaker™, L-DOS47, on CEACAM6-expressing tumors. The study demonstrated that L-DOS47 effectively neutralizes the acidic tumor microenvironment, which is crucial for tumor progression, and showed promising results in head and neck cancer and colon adenocarcinoma models. These findings suggest that L-DOS47 could make hard-to-treat cancers more susceptible to treatment, potentially enhancing Helix’s position in the oncology field.
Helix BioPharma Corp. has strengthened its leadership team by appointing three renowned experts in oncology and drug development. These strategic hires are aimed at advancing Helix’s clinical development and discovery strategies, particularly in enhancing the efficacy of immune-oncology therapies and developing next-generation targeted therapies. The new appointments are expected to significantly impact Helix’s operations and bolster its position in the oncology industry.
Helix BioPharma Corp. has announced the extension of its Annual General and Special Meeting to March 26, 2025, to allow more time for shareholder approval of proposed asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG, as well as a proposed financing strategy. This extension, approved by the Ontario Superior Court of Justice, is a strategic move to strengthen the company’s asset base and financial positioning, potentially impacting its market standing and stakeholder interests.
Helix BioPharma Corp. has postponed its Annual General and Special Meeting to March 26, 2025, to allow more time for shareholder approval on significant asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG, along with a proposed financing strategy. This extension, supported by the Toronto Stock Exchange and pending a court application, highlights Helix’s strategic efforts to enhance its operational capabilities and financial structure, which could potentially strengthen its position in the oncology sector.